Vol 8 Issue 7

CELL AND GENE THERAPY INSIGHTS

Vol 8 Issue 7

Cell and Gene Therapy Insights Vol 8 Issue 7

Download PDF

Featuring

Issue Spotlight: New horizons in cellular immunotherapy
Upstream Bioprocessing 2022
Other articles

New horizons in cellular immunotherapy

Interview

Advancing genome edited allogeneic cell therapies into the clinic

Advancing genome edited allogeneic cell therapies into the clinic

Ensuring commercial readiness in the cellular cancer immunotherapy space

Ensuring commercial readiness in the cellular cancer immunotherapy space

Julian Adams, Michele Korfin, Ronit Simantov

Podcast

Working together to safely advance cell & gene therapies

Working together to safely advance cell & gene therapies

J Maher, A J King, F Neethling et al.

11 September 2022

Expert Roundtable

Autologous versus allogeneic: the future of manufacturing and standardization in cell therapies

Autologous versus allogeneic: the future of manufacturing and standardization in cell therapies

Rupa Pike, Delara Motlagh, Patrick Hanley

FastFacts

Scalable production of lipid nanoparticles for effective gene delivery

Scalable production of lipid nanoparticles for effective gene delivery

11 October 2022

Viewpoint

In vivo engineering of CAR T cell therapies

In vivo engineering of CAR T cell therapies

Haig Aghajanian

A journey in synthetic biology: using gene circuit technology in immuno-oncology

A journey in synthetic biology: using gene circuit technology in immuno-oncology

Timothy Lu, James Collins

The power of combining iPSC-derived NK cell therapy & NK-cell engager antibodies

The power of combining iPSC-derived NK cell therapy & NK-cell engager antibodies

Dr Wei Li, Dr Daniel Teper

Upstream Bioprocessing 2022

Innovator Insight

Complete system for AAV production for clinical production: part 1 – upstream

Complete system for AAV production for clinical production: part 1 – upstream

Jonathan Zmuda, Jenny England

25 October 2022

Why Pall’s Allegro™ Stirred-Tank Bioreactor is ideal for viral vector cell culture

Why Pall’s Allegro™ Stirred-Tank Bioreactor is ideal for viral vector cell culture

E Cameau, E Asilonu, S Bah et al.

Interview

Driving significant AAV process yield and quality improvements for systemic delivery

Driving significant AAV process yield and quality improvements for systemic delivery

Rahul Chelikani

Podcast

Achieving better AAV vector productivity and product quality

Achieving better AAV vector productivity and product quality

Diane Golebiowski, Marissa Stanvick

FastFacts

Leveraging a scalable, standardized platform process for suspension-based AAV and LV vector manufacture to accelerate time to clinic

Leveraging a scalable, standardized platform process for suspension-based AAV and LV vector manufacture to accelerate time to clinic

Journal articles

Innovator Insight

Possibilities for continuous closed-system processing of cell therapies

Possibilities for continuous closed-system processing of cell therapies

S Werner, S Thompson, R Day et al.

Simplifying residual DNA analysis in viral vector production: focus on E1A

Simplifying residual DNA analysis in viral vector production: focus on E1A

Podcast

Accelerating cures: funding stem cell innovation & ideas in an evolving cell therapy space

Accelerating cures: funding stem cell innovation & ideas in an evolving cell therapy space

Amritha Jaishankar

Conference Insight

Achieve commercial success: the value of a sound manufacturing strategy

Achieve commercial success: the value of a sound manufacturing strategy

FastFacts

Tips and tricks for transfection, adaptation, and scale-up for AAV production

Tips and tricks for transfection, adaptation, and scale-up for AAV production

POROSTM CaptureSelectTM AAVX elution optimization study for optimized recovery of AAV6 capsids

POROSTM CaptureSelectTM AAVX elution optimization study for optimized recovery of AAV6 capsids

Viewpoint

Lessons in scientific endeavor and innovation

Lessons in scientific endeavor and innovation

Irving Weissman

3 September 2022

Poster

How can we maximize the efficiency of large-scale LV vector production?

How can we maximize the efficiency of large-scale LV vector production?

Scalable solutions for cell isolation and expansion

Scalable solutions for cell isolation and expansion